291 related articles for article (PubMed ID: 36048895)
1. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
2. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
[No Abstract] [Full Text] [Related]
3. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
4. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
6. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
7. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
[No Abstract] [Full Text] [Related]
8. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
9. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
10. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
11. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy.
Igho-Osagie E; Puenpatom A; Williams MG; Song Y; Yi D; Wang J; Berman R; Gu M; He C
J Manag Care Spec Pharm; 2023 May; 29(5):509-518. PubMed ID: 36989455
[No Abstract] [Full Text] [Related]
12. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
[No Abstract] [Full Text] [Related]
13. Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States.
Klink AJ; Chmielowski B; Feinberg B; Ahsan S; Nero D; Liu FX
J Manag Care Spec Pharm; 2019 Aug; 25(8):869-877. PubMed ID: 30945965
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
15. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
[TBL] [Abstract][Full Text] [Related]
17. Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States.
Vu M; Duhig AM; Tibrewal A; Campbell CM; Gaur A; Salomon C; Gupta A; Kruse M; Taraman S
J Manag Care Spec Pharm; 2023 Apr; 29(4):378-390. PubMed ID: 36989447
[No Abstract] [Full Text] [Related]
18. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population.
Chung H; Crowe CL; Kong SX; Singh R; Farej R; Elliott J; Williamson T; Willey VJ
J Manag Care Spec Pharm; 2023 Jan; 29(1):80-89. PubMed ID: 36580126
[No Abstract] [Full Text] [Related]
19. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
[No Abstract] [Full Text] [Related]
20. Health care utilization and costs associated with functional status in patients with psoriatic arthritis.
Ogdie A; Hwang M; Veeranki P; Portelli A; Sison S; Shafrin J; Pedro S; Hass S; Hur P; Kim N; Yi E; Michaud K
J Manag Care Spec Pharm; 2022 Sep; 28(9):997-1007. PubMed ID: 36001101
[No Abstract] [Full Text] [Related]
[Next] [New Search]
